Oasmia Extends Contract Manufacturing Agreement With Baxter

Oasmia Pharmaceutical AB announced in a press release that it has signed a Master Services Agreement with Baxter BioPharma Solutions, the contract manufacturing organization (CMO) division of Baxter International. The agreement is an extension of previous agreements between the two companies and the initial focus is on an oncology candidate, Doxophos.

Julian Aleksov, CEO and President of Oasmia, said, “The extended agreement will secure large-scale manufacturing to meet future market demands of Oasmia’s products.”

Oasmia and Baxter BioPharma Solutions Collaboration

The previous agreement between Baxter and Oasmia, entered into in March 2011, centered on Oasmia’s oncology candidates Paclical and Paccal Vet-CA1. The collaboration successfully validated large-scale production at the Baxter Halle facility. The two companies expect regulatory authorities to approve production so Oasmia can meet increasing demand for its products. The new agreement complements the previous agreements and covers future Oasmia products in clinical or development phase. The initial focus for the new project is developing Doxophos, in Phase I planning stages for the treatment of human breast cancer.

Baxter BioPharma Solutions

Baxter BioPharma Solutions has over 50 manufacturing sites worldwide on six continents. Facilities in the U.S., Latin America, and Europe provide sterile and cGMP manufacturing. In the U.S., facilities include Bloomington, IN, Hayward, CA, and Round Lake, IL. In 2013, Baxter expanded its cytotoxic contract manufacturing facility in Halle (Westfalen), Germany. Previously, the company expanded that site in 2007 and 2011. The most recent expansion was due to the increase in demand for cancer drugs and is expected to be complete in 2015.

Oasmia Pharmaceutical  

Oasmia Pharmaceutical AB was founded in 1999 and is headquartered in Sweden. It develops human and veterinary oncology drugs. The company focuses on drug-delivery systems, nanoparticle formulations, and cytostatics, which stop cancer cells from growing and multiplying. Oasmia works with Medison Pharma Ltd. to distribute Paclical in Israel and Turkey. The Food and Drug Administration (FDA) issued MUMS (Minor Use designation, which allows for seven years marketing exclusivity) for Paccal Vet in 2011 and 2012 for Squamous Cell Carcinoma and nonresectable stage III, IV, or V mammary carcinoma, respectively.

Recently, Oasmia announced it had made an agreement with an unnamed global pharmaceutical company, which is to use Oasmia’s patented nanoparticle formulation technology XR-17.